Effect of afobazole administered to pregnant rats during organogenesis on prenatal development of fetuses.
Experiments on pregnant rats have demonstrated the absence of damaging effect of Afobazole administered during the antenatal period on organogenesis in fetuses. Afobazole in a dose of 5 mg/kg given to pregnant rats on gestation days 6-16 reduced pre- and post-implantation fetal mortality and improved fertility; 20-day-old embryos had no developmental abnormalities and did not differ from controls by craniocaudal size, body weight, and skeleton ossification. Afobazole in a dose of 100 mg/kg reduced pre- and post-implantation fetal mortality, but had no effect on fertility. No congenital malformations were found in the fetuses, but they were characterized by lower craniocaudal size, body weight, and number of ossification foci in the sternum and spine.
Research Institute of Pharmacology, Volgograd State Medical University, Ministry of Health of the Russian Federation, Volgograd, Russia, lb.bugaeva@rambler.ru.
L I
LI
Bugayova
T D
TD
Denisova
Yu A
YA
Morozova
S A
SA
Sergeeva
I V
IV
Kharlamov
D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use / Q000633:toxicity*; D001562:Benzimidazoles / Q000627:therapeutic use / Q000633:toxicity*; D004353:Drug Evaluation, Preclinical; D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D008297:Male; D008431:Maternal-Fetal Exchange; D009025:Morpholines / Q000627:therapeutic use / Q000633:toxicity*; D038081:Organogenesis / Q000187:drug effects*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D051381:Rats
C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D014151:Anti-Anxiety Agents; D001562:Benzimidazoles; D009025:Morpholines